-The Hindu Justice Prabha Sridevan’s judgment permitting the production and sale of a generic version of a cancer drug is a victory for patients. It posits the public interest, especially in matters of health care, right at the heart of intellectual property rights in India Monday was a remarkable day for cancer patients in India. To them, the country said — “we care.” I am talking about the astounding decision by Justice...

-Global Research The widely held belief is that genetically modified ‘terminator seeds’ are not available on the commercial market anywhere. Since 2001, there has been a de facto worldwide moratorium on the use of terminator technology (UN Convention on Biological Diversity). By definition, such seeds are genetically engineered to make them sterile and unusable for replanting, resulting in farmers having to buy new seeds from a central supplier each year. Under Article...

It is said that only God and a few good men and women run India. One such man is P H Kurien. For readers unfamiliar with his name, Kurien was India's Controller General of Patents, Designs & Trade Marks until March 12, 2012. On March 9, 2012, just three days before he left office, he issued the first-ever compulsory licence in India for the manufacture of a drug still under patent....

-The Hindu Unnerved by the Indian stand, IT monopolies are propagating the myth that a multilateral governance structure will kill the decentralised, multi-stakeholder nature of the Internet and lead to ‘government control' Last year, in a statement to the U.N. General Assembly, India sought the creation of a U.N. Committee on Internet-Related Policies (CIRP) in order to democratise global Internet governance, which at present is either U.S.-controlled, or subject to the policies...

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...